Cognition Therapeutics
CGTX
48 hedge funds and large institutions have $3.5M invested in Cognition Therapeutics in 2025 Q2 according to their latest regulatory filings, with 7 funds opening new positions, 10 increasing their positions, 7 reducing their positions, and 10 closing their positions.
43% more repeat investments, than reductions
Existing positions increased: 10 | Existing positions reduced: 7
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.66% less ownership
Funds ownership: 18.76% → 18.1% (-0.66%)
6% less funds holding
Funds holding: 51 → 48 (-3)
28% less capital invested
Capital invested by funds: $4.89M → $3.5M (-$1.39M)
30% less first-time investments, than exits
New positions opened: 7 | Existing positions closed: 10
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
C
Chescapmanager
Baltimore,
Maryland
|
+$170K |
| 2 |
Vanguard Group
Malvern,
Pennsylvania
|
+$22K |
| 3 |
EWM
Empirical Wealth Management
Seattle,
Washington
|
+$16.2K |
| 4 |
NL
NWAM LLC
Mercer Island,
Washington
|
+$14.4K |
| 5 |
Renaissance Technologies
New York
|
+$13.7K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SPC
Sigma Planning Corp
Ann Arbor,
Michigan
|
-$155K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$103K |
| 3 |
CM
CM Management
Gulf Breeze,
Florida
|
-$50.6K |
| 4 |
BlackRock
New York
|
-$26.2K |
| 5 |
VPIM
Vanguard Personalized Indexing Management
Oakland,
California
|
-$23.6K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
51
SG Americas Securities
New York
| – | -$10K | -23,107 | Closed |
|
|
GCP
52
GSA Capital Partners
London,
United Kingdom
| – | -$9K | -22,354 | Closed |
|
53
Osaic Holdings
Scottsdale,
Arizona
| – | -$3.02K | -7,200 | Closed |
|
|
TRCT
54
Tower Research Capital (TRC)
New York
| – | -$1.03K | -2,444 | Closed |
|
|
CCM
55
Coldstream Capital Management
Bellevue,
Washington
| – | -$524 | -1,243 | Closed |
|
56
JP Morgan Chase
New York
| – | -$29 | -69 | Closed |
|
CGTX Hedge Fund Activity: Q2 2025 in Review
48 of the 7,596 institutional investors tracked by Wall St. Rank reported a position in Cognition Therapeutics (CGTX) for Q2 2025, worth a combined $3.5M — down 28% from $4.89M a quarter earlier.
Sellers outnumbered buyers: 10 funds closed out of CGTX and 7 opened new positions — a net loss of 3 holders — while 7 trimmed existing stakes and 10 added.
The largest buyer was Chescapmanager, opening a new position worth an estimated $170K. The largest seller was Sigma Planning Corp, cutting an estimated $155K.
- 48 institutional investors held Cognition Therapeutics (CGTX) as of Q2 2025, down from 51 in Q1 2025.
- Funds reported $3.5M of Cognition Therapeutics stock for Q2 2025, down 28% quarter-over-quarter.
- 7 funds opened new Cognition Therapeutics positions in Q2 2025 and 10 closed out, a net change of -3 holders.
- The largest Cognition Therapeutics buyer in Q2 2025 was Chescapmanager, an estimated $170K added.
- The largest Cognition Therapeutics seller in Q2 2025 was Sigma Planning Corp, an estimated $155K sold.
Based on aggregated 13F filings for Q2 2025.